AU Patent

AU688168B2 — 5-HTht1f mediated inhibition of neurogenic meningeal extravasation

Assigned to Eli Lilly and Co · Expires 1998-03-05 · 28y expired

What this patent protects

Patent listed against lasmiditan-succinate.

Drugs covered by this patent

lasmiditan-succinate (LASMIDITAN SUCCINATE)

Patent Metadata

Patent number: AU688168B2
Jurisdiction: AU
Classification: —
Expires: 1998-03-05
Drug substance claim: No
Drug product claim: No
Assignee: Eli Lilly and Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.